Steven M. Devine

Steven M. Devine

Hematology
700 Ackerman Rd Ste 260
Columbus, OH 43202

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 243 publications

Umbilical Cord Blood Donor Outcomes in BMTCTN1702.

Umbilical Cord Blood Donor Outcomes in BMTCTN1702.

Journal: Blood advances
Published: August 03, 2026

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

Journal: American journal of hematology
Published: May 29, 2026

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Outcomes after 7/8 and <7/8 mismatched unrelated donor PBSC transplantation with PTCy: results from the ACCESS trial.

Journal: Blood advances
Published: May 12, 2026

Hematopoietic Cell Transplant Access and Patient Diversity.

Hematopoietic Cell Transplant Access and Patient Diversity.

Journal: JAMA network open
Published: May 05, 2026

Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization.

Same-day rescue plerixafor during leukapheresis is safe and effective in allogeneic donors suboptimally responding to granulocyte colony-stimulating factor mobilization.

Journal: Transfusion
Published: April 27, 2026

Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS Trial.

Infection Burden in Mismatched Unrelated Donor Hematopoietic Cell Transplantation: Results from the ACCESS Trial.

Journal: Blood advances
Published: April 24, 2026

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Journal: Blood advances
Published: March 25, 2026

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.

Journal: Blood advances
Published: March 09, 2026

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Donor-specific transplant outcomes from BMT CTN 1702: a multicenter prospective biologic assignment trial.

Journal: Blood advances
Published: March 09, 2026

When remission alone might be good enough.

When remission alone might be good enough.

Journal: Blood advances
Published: February 24, 2026

When remission alone might be good enough.

When remission alone might be good enough.

Journal: Blood advances
Published: February 17, 2026

Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma.

Phase I Trial of Venetoclax and BEAM Followed by Autologous Stem Cell Transplant for High-Risk Non-Hodgkin Lymphoma.

Journal: Transplantation and cellular therapy
Published: January 28, 2026
Showing 1-12 of 243

Last Updated: 09/26/2026